Publications by authors named "T Bednarczuk"
Article Synopsis
- An online survey of European thyroid specialists revealed that 28% believe thyroid hormone (TH) treatment may be appropriate for euthyroid patients with growing simple goiters, despite guidelines against this practice.
- There were significant regional differences in support for TH treatment, with only 7% in The Netherlands compared to 78% in the Czech Republic.
- Factors influencing the likelihood of recommending TH included the specialist's age and the historical iodine insufficiency of their region, while gender, country, and economic factors showed weak associations.
Serum thyroid-stimulating hormone (TSH) measurement is the diagnostic cornerstone for primary thyroid dysfunction. There is high inter-individual but limited intra-individual variation in TSH concentrations, largely due to genetic factors. The currently used wide population-based reference intervals may lead to inappropriate management decisions.
View Article and Find Full Text PDFTreatment of Obesity with Thyroid hormones in Europe. Data from the THESIS* Collaboration.
J Endocrinol Invest
January 2025
Purpose: The use of thyroid hormones (TH) to treat obesity is unsupported by evidence as reflected in international guidelines. We explored views about this practice, and associations with respondent characteristics among European thyroid specialists.
Methods: Specialists from 28 countries were invited to a survey via professional organisations.
Article Synopsis
- - The study aimed to assess how European thyroid specialists view levothyroxine (LT4) treatment for euthyroid women with positive thyroid peroxidase antibodies (TPOAb) to improve fertility, as current evidence does not support this practice.
- - An international survey (THESIS) revealed that 42.8% of over 2,316 respondents believe LT4 might be indicated for these patients, with significant variation across countries, highlighting a range from 22.9% to 83.7% of positive responses.
- - Factors such as gender, age, and clinical experience influenced opinions; younger specialists and those who treat more thyroid patients were more likely to consider LT4, raising concerns about potential overtreatment risks in